{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/CRSP/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-18T16:01:35.950Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9157,"canonical_name":"CRISPR Therapeutics AG","cik":"0001674416","uei":null,"lei":null,"duns":null,"ticker":"CRSP"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":24,"clinical":3},"count":27,"timeline":[{"ts":"2026-10-15","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-10-15","url_slug":"/sec/cik-0001674416/4/0001193125-26-423056","accession_number":"0001193125-26-423056","importance":30},{"ts":"2026-10-15","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-10-15","url_slug":"/sec/cik-0001674416/4/0001193125-26-423057","accession_number":"0001193125-26-423057","importance":30},{"ts":"2026-10-08","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-10-08","url_slug":"/sec/cik-0001674416/4/0001193125-26-418101","accession_number":"0001193125-26-418101","importance":30},{"ts":"2026-10-06","kind":"sec.filing","form_type":"144","title":"144 — CRISPR Therapeutics AG — 2026-10-06","url_slug":"/sec/cik-0001674416/144/0001950047-26-010087","accession_number":"0001950047-26-010087","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-09-24","url_slug":"/sec/cik-0001674416/4/0001193125-26-401237","accession_number":"0001193125-26-401237","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"144","title":"144 — CRISPR Therapeutics AG — 2026-09-22","url_slug":"/sec/cik-0001674416/144/0001950047-26-009755","accession_number":"0001950047-26-009755","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — CRISPR Therapeutics AG — 2026-08-14","url_slug":"/sec/cik-0001674416/schedule-13g-a/0000940594-26-000049","accession_number":"0000940594-26-000049","importance":30},{"ts":"2026-08-11","kind":"clinical.trial","reporter":"CRISPR Therapeutics AG","title":"A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07758634","excerpt":"[\"Hypertension\"]","importance":45},{"ts":"2026-08-11","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-08-11","url_slug":"/sec/cik-0001674416/4/0001193125-26-345111","accession_number":"0001193125-26-345111","importance":30},{"ts":"2026-08-07","kind":"sec.insider.g","reporter":"Prasad Raju","title":"Chief Financial Officer","shares":750,"price_per_share":0,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-08-03","kind":"sec.filing","form_type":"10-Q","title":"10-Q — CRISPR Therapeutics AG — 2026-08-03","url_slug":"/sec/cik-0001674416/10-q/0001193125-26-330672","accession_number":"0001193125-26-330672","importance":45},{"ts":"2026-08-03","kind":"sec.filing","form_type":"8-K","title":"8-K — CRISPR Therapeutics AG — 2026-08-03","url_slug":"/sec/cik-0001674416/8-k/0001193125-26-330644","accession_number":"0001193125-26-330644","importance":35},{"ts":"2026-07-27","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — CRISPR Therapeutics AG — 2026-07-27","url_slug":"/sec/cik-0001674416/schedule-13g-a/0002012383-26-002146","accession_number":"0002012383-26-002146","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-06-09","url_slug":"/sec/cik-0001674416/4/0001193125-26-264289","accession_number":"0001193125-26-264289","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-06-09","url_slug":"/sec/cik-0001674416/4/0001193125-26-264279","accession_number":"0001193125-26-264279","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-06-09","url_slug":"/sec/cik-0001674416/4/0001193125-26-264282","accession_number":"0001193125-26-264282","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"S-8","title":"S-8 — CRISPR Therapeutics AG — 2026-06-05","url_slug":"/sec/cik-0001674416/s-8/0001193125-26-258473","accession_number":"0001193125-26-258473","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — CRISPR Therapeutics AG — 2026-06-04","url_slug":"/sec/cik-0001674416/8-k/0001193125-26-257593","accession_number":"0001193125-26-257593","importance":35},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-06-02","url_slug":"/sec/cik-0001674416/4/0001193125-26-253925","accession_number":"0001193125-26-253925","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-06-02","url_slug":"/sec/cik-0001674416/4/0001193125-26-253926","accession_number":"0001193125-26-253926","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-06-02","url_slug":"/sec/cik-0001674416/4/0001193125-26-253929","accession_number":"0001193125-26-253929","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — CRISPR Therapeutics AG — 2026-06-01","url_slug":"/sec/cik-0001674416/4/0001193125-26-251817","accession_number":"0001193125-26-251817","importance":30},{"ts":"2026-05-29","kind":"sec.insider.s","reporter":"Patel Naimish","title":"Chief Medical Officer","shares":3786,"price_per_share":55.62,"usd_value":210577,"security_title":"Common Shares","importance":35.21057732},{"ts":"2026-05-28","kind":"sec.insider.m","reporter":"Patel Naimish","title":"Chief Medical Officer","shares":10000,"price_per_share":null,"usd_value":0,"security_title":"Common Shares","importance":15},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — CRISPR Therapeutics AG — 2026-05-15","url_slug":"/sec/cik-0001674416/schedule-13g-a/0000940594-26-000027","accession_number":"0000940594-26-000027","importance":30},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"CRISPR Therapeutics AG","title":"An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D","security_title":"PHASE1","status":"TERMINATED","accession_number":"NCT05565248","excerpt":"Patients to be followed up in the VCTX-201 study","importance":80},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"CRISPR Therapeutics AG","title":"Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease","security_title":"PHASE1,PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07549698","excerpt":"[\"Warm Autoimmune Hemolytic Anemia (WAIHA)\",\"ITP - Immune Thrombocytopenia\",\"Warm Autoimmune Hemolytic Anemia\",\"Immune Thrombocytopenic Purpura\"]","importance":45}]}